Entrada Therapeutics, Inc. — Q3 2021 Form 10-Q
Business context and reporting period
Unaudited results for the quarter and nine months ended September 30, 2021, compared with the corresponding 2020 periods. Entrada is a preclinical-stage biotechnology company developing intracellular therapeutics using its Endosomal Escape Vehicle (EEV) platform. It had no product revenue and had not initiated clinical trials; its lead candidate, ENTR-601-44, was in preclinical development.
Financial results and liquidity
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $10.5 million | $5.7 million | $23.6 million | $14.4 million |
| General and administrative expense | $3.9 million | $1.3 million | $9.1 million | $3.6 million |
| Total operating expense | $14.4 million | $7.0 million | $32.7 million | $18.0 million |
| Net loss | $14.4 million | $7.0 million | $32.7 million | $17.9 million |
| Net loss per share, basic and diluted | $9.78 | $6.13 | $24.18 | $16.55 |
At September 30, 2021, cash and cash equivalents were $122.2 million, current assets $123.5 million, total assets $132.4 million, total liabilities $7.5 million, and accumulated deficit $75.2 million. The company reported no debt. Profitability and operating margins are not meaningful because it had no revenue and incurred operating losses.
For the first nine months of 2021, operating cash used was $30.3 million, investing cash used was $3.3 million, and financing cash provided was $116.7 million, primarily from $115.8 million net proceeds from Series B preferred stock. Cash increased by $83.1 million from year-end 2020. Operating lease obligations totaled $18.6 million, including $8.0 million due within one year; these are commitments, not debt.
Material changes versus the prior comparable period
Q3 operating expenses increased $7.4 million year over year; nine-month expenses increased $14.7 million. Management attributed the increases mainly to higher R&D and administrative headcount, increased laboratory spending, and facility and equipment costs. Nine-month net loss widened by $14.9 million. Cash and cash equivalents rose from $39.0 million at December 31, 2020, primarily reflecting the Series B financing.
Outlook, risks, contingencies, and unusual items
- Management expected R&D spending to rise as programs advance and IND-enabling work proceeds. It planned to advance ENTR-601-44 toward an IND submission in 2022 and an exon 45 candidate toward an IND submission in 2023; both were forward-looking targets, not completed milestones.
- The filing’s liquidity estimates differ by scope and timing: the financial-statement note says September 30 cash alone was expected to fund operations and capital needs for at least 12 months from issuance; MD&A says September 30 cash plus subsequent IPO proceeds was expected to fund operations into the second half of 2024. Management cautioned that assumptions could prove incorrect and additional financing would eventually be needed.
- In November 2021, after the reporting date, Entrada completed its IPO, selling 10,436,250 shares at $20.00 each for $208.7 million gross proceeds and approximately $190.9 million net proceeds. All outstanding preferred stock converted into 19,185,183 common shares. The filing also reports an October 22, 2021 1-for-7.235890014 reverse stock split; per-share amounts were adjusted retroactively.
- Principal risks include the unproven EEV approach, preclinical and regulatory uncertainty, dependence on ENTR-601-44, manufacturing scale-up and third-party suppliers, patent and licensing protection, competition, future financing needs, and possible COVID-19-related disruption. The company reported temporary operational reductions at certain vendors during the pandemic, which had normalized; it reported no material pandemic-related financial impact to date.
- No material litigation was pending, and the company reported no off-balance-sheet arrangements. Management concluded disclosure controls were effective as of September 30, 2021.
Important facts for investors to verify
- Progress against the stated ENTR-601-44 and exon 45 IND timelines, and the evidence supporting advancement from preclinical development.
- Actual cash burn, spending growth, and whether the stated runway through the second half of 2024 remains valid as programs and public-company costs expand.
- Manufacturing readiness, supply-chain resilience, and any new safety, efficacy, or regulatory findings for the EEV platform and candidates.
- IPO net proceeds, post-IPO share count and dilution, including equity-plan and employee stock-purchase-plan issuances.
- Material developments in intellectual-property rights, licenses, collaborations, lease commitments, or other contingencies.